Similarly, BRAF V600E-positive mutation metastatic melanoma patients treated with targeted therapies (BRAF/MEK inhibitors) have shown superior progression-free survival compared to those treated with cytotoxic chemotherapy in the BREAK-3 (dabrafenib versus dacarbazine )[5, 6] and METRIC trials (trametinib versus various chemotherapies )[7, 8]. The gene discussed is BRAF; the disease is metastatic melanoma.